UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 12, 2013

Cadence Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**001-33103**	**41-2142317**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

12481 High Bluff Drive, Suite 200
San Diego, California 92130
(Address of principal executive offices, including zip code)

(858) 436-1400
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On December 16, 2013, Cadence Pharmaceuticals, Inc. (the "Company" or "Cadence") updated its corporate presentation. Cadence maintains the current version of its corporate presentation on the Investors page of www.cadencepharm.com under "Events & Presentations" and then "Corporate Overview." The corporate presentation is also attached as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference. Cadence will present its corporate presentation during meetings with investors, analysts and others, at the Guggenheim Securities Boston Healthcare Day – Life Sciences conference on December 17, 2013.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this item of this report.

Item 8.01. Other Events.

On December 12, 2013, Cadence received a notice from Wockhardt USA LLC ("Wockhardt"), a New Jersey-based company, stating that Wockhardt filed an Abbreviated New Drug Application ("ANDA") containing a "Paragraph IV" patent certification with the U.S. Food and Drug Administration (the "FDA") for a generic version of Cadence's drug, OFIRMEV® (acetaminophen) injection (1000 mg/100 mL, 10 mg/mL). This notice states that the "Paragraph IV" patent certification was made with respect to both patents for OFIRMEV listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. A Paragraph IV patent certification is a certification by a generic applicant that, in the opinion of that applicant, the patent listed in the Orange Book for a branded product is invalid, unenforceable, or will not be infringed by the manufacture, use or sale of the generic product. Cadence is currently reviewing the details of the notice. Under the Federal Food, Drug, and Cosmetic Act and the FDA's implementing regulations, the filing of a patent infringement lawsuit within 45 days of the receipt of notice of a Paragraph IV patent certification automatically prevents the FDA from approving the ANDA until the earlier of the expiration of a 30-month period, the expiration of the patents, the entry of a settlement order stating that the patents are invalid or not infringed, a decision in the infringement case that is favorable to the ANDA applicant, or such shorter or longer period as the court may order. Cadence intends to vigorously enforce its intellectual property rights relating to OFIRMEV, but cannot predict the outcome of this matter or guarantee the outcome of any litigation. OFIRMEV is protected by two patents, both of which are listed in the Orange Book.

For a discussion of risks related to the ANDA filing by Wockhardt, see the discussion of "Intellectual Property" under the "Business" section of Cadence's Annual Report on Form 10-K for the year ended December 31, 2012 filed with the Securities and Exchange Commission (the "SEC") on March 8, 2013, and the "Risk Factors" section of Cadence's Quarterly Report on Form 10-Q for the period ended September 30, 2013 filed with the SEC on November 6, 2013, including the risks described under the heading "The patent rights that we have in-licensed covering OFIRMEV are limited to a specific IV formulation of acetaminophen. As a result, our market opportunity for this product may be limited by the lack of patent protection for the active ingredient itself and other formulations of IV acetaminophen may be developed by competitors," as well as any updates to such sections contained in Cadence's subsequent reports filed with the SEC.

Statements included in this report that are not a description of historical facts are forward-looking statements. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Such statements include, without limitation, statements regarding: Cadence's intention to vigorously enforce its intellectual property rights. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Cadence's actual future results may differ materially from Cadence's current expectations due to the risks and uncertainties inherent in its business. These risks include, but are not limited to: Cadence's ability to successfully enforce its marketing exclusivities and intellectual property rights, and to defend its patents; the potential that Cadence may be required to file lawsuits to defend its patent rights from

challenges by companies seeking to market generic versions of intravenous acetaminophen, and the substantial costs associated with such lawsuits; the possible introduction of generic competition to OFIRMEV; Cadence's dependence on its licensors for the maintenance and enforcement of its intellectual property rights; Cadence's dependence on the successful commercialization of OFIRMEV, which is the company's only product; Cadence's ability to ensure an adequate and continued supply of OFIRMEV to meet anticipated market demand; the risk that Cadence may not be able to raise sufficient capital when needed, or at all, and other risks detailed under "Risk Factors" and elsewhere in Cadence's periodic reports and other filings made with the SEC from time to time. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995, and the company undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description of Exhibit
99.1	Corporate Presentation, dated December 16, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CADENCE PHARMACEUTICALS, INC.

By: /s/ William R. LaRue
William R. LaRue
Senior Vice President, Chief Financial Officer, Treasurer and Assistant Secretary

Date: December 16, 2013

EXHIBIT INDEX

Exhibit Number	Description of Exhibit
99.1	Corporate Presentation, dated December 16, 2013

EXHIBIT 99.1

cadence™ PHARMACEUTICALS

Improving the lives of hospitalized patients

Corporate Presentation

December 16, 2013

Caution on forward-looking statements

This presentation includes forward-looking statements, which are based on our current beliefs and expectations. Such statements include, without limitation, statements regarding: the anticipated U.S. market opportunity for OFIRMEV; our financial estimates and projections; our expectations regarding growth in customer base, frequency of product use, order rates, share of surgical patients, utilization per patient, expectations for future use, and their ability to drive revenue growth for OFIRMEV; the sustainability of our core business; the sufficiency of our capital resources to fund our operations; and our ability to execute our strategies for acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Our actual future results may differ materially from our current expectations due to the risks and uncertainties inherent in our business. In addition, past results and trends may not be indicative or a guarantee of future results or trends. These risks include, but are not limited to: our dependence on the successful commercialization of OFIRMEV, which is our only product; our ability to achieve broad market acceptance and generate revenues from sales of OFIRMEV; our ability to successfully enforce our marketing exclusivities and intellectual property rights and to defend the patents covering OFIRMEV, including in our current and any future, additional intellectual property litigation and U.S. patent office challenges; the potential introduction of generic competition to OFIRMEV; our dependence on our contract manufacturers and our ability to ensure an adequate and continued supply of OFIRMEV to meet market demand; potential product liability exposure; the risk that we may not be able to raise sufficient capital when needed, or at all; and other risks detailed under “Risk Factors” and elsewhere in our most recent Quarterly Report on Form 10-Q, and our other filings made with the Securities and Exchange Commission from time to time.

All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and we undertake no obligation to revise or update this presentation to reflect events or circumstances after the date hereof.

Investment highlights

- Specialty biopharmaceutical company, focused on developing and commercializing proprietary therapeutics utilized in the hospital setting
  - OFIRMEV® (acetaminophen) injection – indicated for use in adults and children ≥2yrs for the:
    - Management of mild to moderate pain
    - Management of moderate to severe pain with adjunctive opioid analgesics
    - Reduction of fever
- A differentiated, new class of IV pain medication
  - Non-opioid, non-NSAID analgesic
  - Foundation for multimodal approach to pain management
- Widespread hospital formulary adoption and positive physician feedback
- Solid revenue growth driven by a growing customer base, increasing re-order rates and penetration in a variety of surgical settings
- Sustainable OFIRMEV core business brings opportunities to diversify product portfolio and leverage existing sales infrastructure

OFIRMEV® (acetaminophen) injection

- Proprietary IV acetaminophen formulation
- First and only IV formulation of acetaminophen approved in the United States
- New class of IV medication
  - non-narcotic / opioid
  - non-NSAID
- Same formulation of IV acetaminophen marketed by BMY in Europe since 2002 as Perfalgan™

PERFALGAN™ is a trademark of Bristol-Myers Squibb Company.

Strong foundation for commercial success

Effective Pain Control

- Significant pain relief[1]
- Reduced opioid consumption[1]*
- Improved patient satisfaction[1],[2]

Experienced Hospital Sales Force

- Sales force average >10 years hospital selling experience
- Extensive relationships, significant overlap with prior territory
- Substantial hospital commercial experience throughout management
  - CEO > 25 years, CCO > 15 years, VP of Sales > 25 years

Economic Value

- $13.18/ vial**
- Diagnosis-related group payment range for common procedures: $12,000 - $31,000[3]
- OFIRMEV may help reduce post surgical ambulation time[4], time to extubation in the ICU[5], hospital length of stay[6]

References: (1) Sinatra, et al., 2005, (2) Wininger, et al., 2010, (3) Birkmeyer,et al., 2010, (4) Ohnesorge, et al., 2009, (5) Memis, et al., 2010, (6) Zafar, et al., 2010, Arici, et al., 2009

**** Clinical benefit of opioid reduction not evaluated or demonstrated in this study ** WAC, effective July 2, 2013***

Label supports the message



Limitations of other IV pain therapies

Opioids

- Sedation
- Nausea
- Vomiting
- Constipation
- Headache
- Cognitive impairment
- Respiratory depression

- Prolonged recovery
- Increased length of stay
- Higher costs to the institution

NSAIDs

- Bleeding
- GI complications
- Kidney complications
- Cardiovascular risks

- Limited use

Multimodal analgesia is becoming standard

Pain Intensity	Historical US Approach	Emerging US Approach
Severe	**Opioids**	**IV acetaminophen** + opioids
Moderate	**Opioids**	**IV acetaminophen** + opioids, if necessary
Mild	**Opioids**	**IV acetaminophen**

Strong commercial acceptance

- Rapid formulary adoption
  - On formulary in over 2,350 hospitals*
  - Minimal restrictions
- Strong physician support and early experience positive
  - OFIRMEV physician market research:**
    - 97% of physicians surveyed reported that OFIRMEV's efficacy met or exceeded their expectations
    - 3 of 4 indicate they are very likely to recommend to colleagues
- Rapid and sustained sales growth
  - Approximately 13.7 million vials purchased by hospitals***
  - Estimated 5.5 -6.9 million patients treated through Oct. 31, 2013****

* *Launch through October 31, 2013*
** *December 2012 attitude, trial, and usage ("ATU") market research of surgeons and anesthesiologists (n>180) conducted by GfK Healthcare (commissioned by Cadence)*
*** *Cadence internal data through October 31, 2013*
**** *Based on our estimate of 2-2.5 doses per patient*

Strong OFIRMEV® sales growth

- WAC sales reported to be $11.8M for October 2013
- Monthly vial sales of 895K in October 2013

OFIRMEV Monthly Sales



	Jan-11	Feb-11	Mar-11	Apr-11	May-11	Jun-11	Jul-11	Aug-11	Sep-11	Oct-11	Nov-11	Dec-11	Jan-12	Feb-12	Mar-12	Apr-12	May-12	Jun-12	Jul-12	Aug-12	Sep-12	Oct-12	Nov-12	Dec-12	Jan-13	Feb-13	Mar-13	Apr-13	May-13	Jun-13	Jul-13	Aug-13	Sep-13	Oct-13
Monthly Sales ($M)	0.0	0.1	0.2	0.4	0.6	0.9	1.0	1.3	1.5	1.8	2.1	2.5	2.3	3.2	3.3	3.4	4.1	4.4	4.7	5.5	4.9	6.1	6.0	6.4	7.0	7.3	8.3	8.5	9.2	8.9	10.3	10.9	9.8	11.8
Sales/Day ($ 000's)	3.10	4.85	9.78	17.6	28.2	39.4	51.1	56.9	72.0	86.6	103.	124.	103.	151.	147.	163.	188.	208.	221.	237.	256.	264.	300.	338.	317.	365.	395.	387.	419.	443.	467.	495.	491.	512.

Source: Source Healthcare Analytics, Source PHAST Institution, November 20, 2013 and Cadence internal data.

Historical account growth metrics

- Growth in customer base
  - Number of unique customer accounts increased to over 4,600 in Q3 2013
  - Number of repeat customers grew to over 3,900 in Q3 2013 and represents approximately 85% of all customers
- Increase in frequency of product use
  - Hospital reorder rates averaged approximately 4.8 orders per account for Q3 2013, an 8% increase over Q3 2012
- Increase in average quantity of product ordered per customer
  - Average order size in Q3 2013 increased 22% over Q3 2012 to over 105 vials/order
  - Anticipate increasing number of vials per patient as adoption by surgeons broadens



Broad adoption

- As of end of Q3 2013:
  - Over 2,350 hospital formulary approvals
  - Over 4,600 accounts have ordered OFIRMEV



Significant growth in new customers



Significant growth in new and repeat customers each quarter

- **Approximately 33% growth in unique accounts ordering OFIRMEV in Q3 2013 vs. Q3 2012**
- **39% increase in accounts that placed multiple orders in Q3 2013 vs. Q3 2012**

Growing average order size

Growth drivers

- Expanding physician user base*
  - Market research indicates growing user base in targeted accounts
  - Proportion of surgeons using OFIRMEV in targeted accounts has tripled in less than 2 years
- Increasing share of surgical patients
  - Data from Premier healthcare alliance indicates consistent growth through Q2 2013**
- Growing utilization per patient
  - Number of vials used per patient has grown steadily since 2011**
  - Anticipate increasing number of vials per patient as adoption by surgeons broadens

* *ATU surveys conducted from Sept '11 through July '13 indicate (general and orthopedic) surgeon utilization has increased from 23% to 76% during this time period.*

** *Patient discharge data from the hospital research database maintained by the Premier healthcare alliance (October 10, 2013) Sample includes over 400 hospitals representing approximately 4.5M surgical patient discharges/year*

Market research: increasing prescriber base

More physicians in targeted accounts are using OFIRMEV®



Question: Please indicate your experience/familiarity with each of the following product brands. Those indicating "currently use" shown on this chart.

Source: September 2011-December 2012 ATU market research of surgeons and anesthesiologists conducted by GfK Healthcare and July 2013 ATU conducted by Life Science Strategy Group, LLC (commissioned by Cadence)

Increasing share of surgical patients

OFIRMEV® Share of US Hospital Surgical Procedures
(Premier Healthcare Alliance Database)



Source:
Patient discharge data from the hospital research database maintained by the Premier healthcare alliance (October 10, 2013)
Sample includes over 400 hospitals representing approximately 4.5M surgical patient discharges/year

Increasing utilization per patient

OFIRMEV® Vial Utilization – Surgical Inpatient Procedures

(Premier Healthcare Alliance Database)



Source:
Patient discharge data from the hospital research database maintained by the Premier healthcare alliance (October 10, 2013)
Sample includes over 400 hospitals representing approximately 4.5M surgical patient discharges/year

Long term opportunity

Physicians indicate higher expectations for future use of OFIRMEV®



Question (September 2011): What percentage of your (surgical procedures) would you expect to fill for OFIRMEV when you reach the peak usage?

Question (December 2012): Thinking ahead to 3 years from now, in what proportion of your surgical procedures requiring IV analgesics do you expect to include the use of OFIRMEV?

Source: December 2012 ATU market research of surgeons and anesthesiologists (n>180) conducted by GfK Healthcare (commissioned by Cadence)

Long term opportunity: ketorolac as a case study

Benchmarking potential future use of OFIRMEV® against ketorolac utilization

Limitations of NSAIDs

- High Risk of Bleeding
- Contraindicated as prophylactic analgesic prior to any major surgery
- Cardiovascular risks (CV thrombotic events, MI and stroke)
- Renal risks (advanced renal impairment)
- Gastrointestinal risks (active or history of peptic ulcers or GI bleeding)
- Contraindicated in labor & delivery, and in nursing mothers
- Contraindicated in patients receiving aspirin or other NSAIDs

Perioperative Pain Population



Long term opportunity: share of patients

Physicians project OFIRMEV® to be much more broadly utilized than NSAIDs



** Question: Thinking ahead to 3 years from now, what proportion of your surgical procedures do you expect to include the use of OFIRMEV?
Source: ATU study conducted by GfK Healthcare, May 2012 (n=180 surgeons and anesthesiologists)

* Source: Patient discharge data from the hospital research database maintained by the Premier healthcare alliance (October 10, 2013)

Long term opportunity: doses per patient

Physicians project significant increases in doses per patient



Source: Awareness, Trial, Usage Study conducted by Life Science Strategy Group, LLC, July 2013
Question 1: When you use OFIRMEV, how many vials are you using per one typical surgical procedure?
Question 2: How many vials of OFIRMEV do you expect to use per one typical surgical procedure 3 years from now?

Delivering sustainable growth

- Continue to broaden and deepen use of OFIRMEV® treating post-op pain
  - Current trends and primary market research indicate potential for sustained growth in patient share and vials per patient
- Support implementation of multi-modal pain management strategies to help hospitals improve economics and quality outcomes
  - A recently-presented study analyzing a large-scale hospital billing database examined the impact of IV acetaminophen on improving outcomes and cost of care for treating acute pain associated with common joint replacement procedures*
- Launch OFIRMEV flexible bag presentation
  - sNDA expected to be filed Q4 13
  - Anticipated launch Q4 14/Q1 15
- Extend use of OFIRMEV into non-operative acute pain management
  - Non-operative acute pain management estimated to represent 30-40% of IV analgesic use
  - Non-operative applications currently account for only about 10% of OFIRMEV use
- Expand product portfolio through business development transactions

* Evaluation of Patient Outcomes, Length of Stay, and Average Hospital Costs with IV Acetaminophen: A Case-Matched Analysis of a National Inpatient Hospital Database. Christian Apfel, M.D., Ph.D., Adjunct Associate Professor, Department of Epidemiology and Biostatistics, UCSF, San Francisco, CA. (ASHP abstract 3-127)

Business development: target profile

Accelerate growth by leveraging Cadence's existing infrastructure through acquisitions of products or companies

	Near Term	Long Term
Region	**US**	**US / Global***
Channel	**Hospital**	**Hospital****
Product Status & Sales Potential	• **Modest sized marketed or ready-to-launch products**	• **Moderate-large marketed or ready-to-launch products** • **Development-stage assets with significant peak sales potential**
Cost Synergies	• **Will target products that can leverage our hospital-focused commercial infrastructure**	
Deal Structures	• **Will consider transaction structures, incl. co-promotion, asset purchases, and in-licenses**	• **Will consider transaction structures including acquisitions, asset purchases, and in-licenses**

**Anticipate partnering ex-US rights* ***Anticipate partnering non-hospital component*

Financial highlights

	12 mos. ended 12/31/12 (in MM)	9 mos. ended 9/30/13 (in MM)
Net product revenue	$50.1	$77.2
Operating expenses	$103.6	$75.4
Cash, cash equivalents & short-term investments	$62.1	$54.3
Shares outstanding	85.7	86.1

Investment highlights

- Specialty biopharmaceutical company, focused on developing and commercializing proprietary therapeutics utilized in the hospital setting
  - OFIRMEV® (acetaminophen) injection – indicated for use in adults and children ≥2yrs for the:
    - Management of mild to moderate pain
    - Management of moderate to severe pain with adjunctive opioid analgesics
    - Reduction of fever
- A differentiated, new class of IV pain medication
  - Non-opioid, non-NSAID analgesic
  - Foundation for multimodal approach to pain management
- Widespread hospital formulary adoption and positive physician feedback
- Solid revenue growth driven by a growing customer base, increasing re-order rates and penetration in a variety of surgical settings
- Sustainable OFIRMEV core business brings opportunities to diversify product portfolio and leverage existing sales infrastructure

Important Safety Information about OFIRMEV (acetaminophen) injection

WARNING: RISK OF MEDICATION ERRORS AND HEPATOTOXICITY

Take care when prescribing, preparing, and administering OFIRMEV Injection to avoid dosing errors which could result in accidental overdose and death.

OFIRMEV contains acetaminophen. Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed the recommended maximum daily limits, and often involve more than one acetaminophen-containing product.

OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. Rarely, acetaminophen may cause serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal.

Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur, or at the first appearance of skin rash. Do not use in patients with acetaminophen allergy.

The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients.

The antipyretic effects of OFIRMEV may mask fever in patients treated with postsurgical pain.

OFIRMEV is approved for use in patients ≥ 2 years of age.

Do not exceed the recommended maximum daily dose of OFIRMEV.

OFIRMEV should be administered only as a 15-minute infusion.

To report SUSPECTED ADVERSE REACTIONS, contact Cadence Pharmaceuticals, Inc. at 1-877-647-2239 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Prescribing Information for OFIRMEV (acetaminophen) injection. San Diego, CA: Cadence Pharmaceuticals, Inc., 2013.